Search

Search Constraints

You searched for: Author/Creator Hawthorne, Thomas

Search Results

1. 107 ReACT: Overall Survival From a Randomized Phase II Study of Rindopepimut (CDX-110) Plus Bevacizumab in Relapsed Glioblastoma. (August 2015)

2. Anti‐KIT antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria. Issue 5 (3rd December 2022)

4. Phase II trial of the glycoprotein non-metastatic B-targeted antibody–drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children's Oncology Group. (November 2019)

5. Students' participation in collaborative research should be recognised. (March 2017)

6. Students' participation in collaborative research should be recognised. (March 2017)

7. Students' participation in collaborative research should be recognised. (March 2017)

8. Targeting Glycoprotein NMB With Antibody‐Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma. Issue 1 (25th August 2015)